上海药明巨诺生物科技有限公司 JW Therapeutics Mediaroom

JW Therapeutics Announces NMPA Acceptance of the Supplemental Biological License Application for Carteyva® in Patients with Relapsed or Refractory Mantle Cell Lymphoma

SHANGHAI, Jan. 4, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative ...

2024-01-04 21:40 1768

JW Therapeutics Announces Exclusive Collaboration with 2seventy bio for Autoimmune Disease CAR-T Therapy

SHANGHAI, Jan. 2, 2024 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biot...

2024-01-02 20:15 1922

JW Therapeutics Announces IND Approval for the Clinical Trial of Relma-cel in Patients with Moderately or Severely Refractory Systemic Lupus Erythematosus

SHANGHAI, April 10, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-04-10 19:30 2703

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

SHANGHAI, March 30, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-03-30 08:00 2214

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 406 Patients

JW Therapeutics Announces Initiation of Clinical Study of Carteyva® in First-line Treatment in Patients with High-Risk Large B-Cell Lymphoma

SHANGHAI, March 8, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovativ...

2023-03-08 17:30 2599

JW Therapeutics Announces Initiation of Clinical Study of JWATM214 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, Feb. 28, 2023 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2023-02-28 17:30 2162

JW Therapeutics Presents Latest Clinical Data on Carteyva® in Follicular Lymphoma and Mantle Cell Lymphoma at the 64th ASH Annual Meeting

SHANGHAI, Dec. 12, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2022-12-12 18:00 4119

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

SHANGHAI, Nov. 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ...

2022-11-09 17:00 3201

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 300 Patients

JW Therapeutics and 2seventy bio Announce Strategic Partnership to Accelerate the Research and Development of T Cell-based Immunotherapies

* Initial focus on accelerating development of 2seventy's MAGE-A4 program in solid tumors inChina...

2022-10-27 07:53 3298

JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Oct. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative...

2022-10-10 20:00 2309

JW Therapeutics Announces Initiation of Clinical Study of JWATM204 in Patients with Advanced Hepatocellular Carcinoma

SHANGHAI, July 4, 2022 /PRNewswire/ -- JW Therapeutics (HKEX: 2126), an independent and innovative ...

2022-07-04 19:30 3463

JW Therapeutics Presents Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, June 5, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative ...

2022-06-05 18:30 3687

JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, May 8, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative b...

2022-05-09 09:00 1732

JW Therapeutics to Present Latest Data of Carteyva® at 2022 ASCO Annual Meeting

SHANGHAI, May 9, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovative b...

2022-05-09 09:00 2289

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

SHANGHAI, April 25, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent and innovativ...

2022-04-25 15:08 2377

JW Therapeutics Announces its Cell Immunotherapy Drugs Have Successfully Benefited 200 Chinese Patients

JW Therapeutics Announces IND Approval for the Clinical Trial of Carteyva® in Pediatric and Young Adult Patients with Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

SHANGHAI, April 20, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative b...

2022-04-20 18:30 2381

JW Therapeutics Announces Receipt of Breakthrough Therapy Designation for Carteyva® in Mantle Cell Lymphoma in China

SHANGHAI, April 3, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bi...

2022-04-03 18:05 3331

JW Therapeutics Announces IND Approval for the Pivotal Clinical Trial of Carteyva® in Second-line Large B-Cell Lymphoma

SHANGHAI, March 31, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative b...

2022-03-31 12:20 2317

JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma

SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bi...

2022-02-27 18:30 3767

JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building

SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative bi...

2022-01-10 09:30 2990

Latest News